Explore the Agenda
7:30 am Morning Breakfast & Registration
8:25 am Chair’s Opening Remarks
Late-Breaking Clinical Data: Analysing the Phase II–III Readouts Reshaping the Future of Radiopharmaceutical Oncology
8:30 am The Site Perspective: Overcoming Operational Barriers to Deliver Successful Radiopharmaceutical Clinical Trials
- Sharing real-world lessons from supporting radiopharmaceutical clinical trials across the NHS, from study set-up through to patient treatment and follow-up
- Exploring the operational challenges associated with dosimetry, pharmacokinetic sampling, radiopharmaceutical handling and cross-functional coordination
- Examining how sponsors and clinical sites can work together more effectively to accelerate study activation and execution
- Identifying opportunities to strengthen collaboration between pharma, biotech and NHS centres to improve trial delivery and patient access to innovative therapies
9:00 am Demonstrating the Clinical Potential of Pb-212 Alpha Therapy: Key Learnings from Phase II AlphaMedix Development
- Presenting Phase II clinical data evaluating the safety, efficacy and therapeutic potential of Pb-212-based targeted alpha therapies
- Exploring how clinical findings are shaping patient selection, dosing strategies and future development decisions
- Examining the key translational and operational learnings generated throughout Phase II development
9:30 am Redefining PRRT: Advancing EBTATE Towards a New Standard of Care for Gastroenteropancreatic Neuroendocrine Tumours
- Presenting the latest clinical data supporting EBTATE, including encouraging efficacy, safety and durability outcomes as the programme advances towards pivotal Phase III evaluation
- Examining how enhanced tumour retention and albumin-binding technology enables meaningful therapeutic responses with substantially lower administered radioactivity and without amino acid co-infusion
- Comparing the clinical and practical implications of next-generation PRRT against existing treatment paradigms to understand where meaningful differentiation can be achieved
10:00 am Morning Break & Networking
Discovery & Preclinical Track
Discovery & Preclinical
From First-in-Class to Best-in-Class: Expanding Novel TRP Targets Beyond PSMA & SSTR to Unlock the Next Wave of Clinical Opportunity
11:00 am Advancing PSMA Radiopharmaceuticals into the Clinic: Lessons Learned from Navigating the CDE Approval Pathway
Chief Scientific Officer, Vitsgen Therapeutics, Inc.
- Sharing the development journey of a PSMA-targeted radiopharmaceutical from preclinical development through to Phase I clinical evaluation
- Exploring key considerations when preparing regulatory submissions to the Chinese CDE and identifying opportunities to accelerate clinical entry
- Understanding the similarities and differences between CDE and FDA expectations for radiopharmaceutical development
- Highlighting practical lessons learned from generating the data package required to support successful first-in-human studies and future global development
11:30 am Reimagining Antibody-Based Radiopharmaceuticals: Using Click-to-Release Technology to Expand the Therapeutic Window Across Multiple Targets
Chief Scientific Officer & Founder, Tagworks Pharmaceuticals BV
- Leveraging preclinical imaging, dosimetry and translational data to demonstrate how click-to-release technology can selectively remove circulating radioactivity whilst preserving tumour-bound activity
- Exploring how established ADC targets and internalisation pathways can be leveraged to accelerate the development of next-generation radiopharmaceutical programmes
- Examining the potential to overcome historical blood and kidney dose limitations associated with antibody-based radiopharmaceuticals and unlock a broader range of therapeutic targets
12:00 pm Moving Beyond Cell Surface Receptors: Advancing First-in-Class Tumour Microenvironment Targets into the Clinic
Chief Executive Officer, Lumina Pharmaceuticals
- Presenting the rationale for targeting the tumour microenvironment as a next-generation approach to radiopharmaceutical development
- Exploring the potential advantages of non-cell receptorbased targeting strategies in expanding patient eligibility and improving therapeutic flexibility
- Sharing lessons learned from advancing a first-in-class radiopharmaceutical programme through Phase 0 clinical evaluation
Translational & Clinical Track
Supply Chain & CMC
12:30 pm Lunch Break
Discovery & Preclinical Track
Expanding TRPs into New Disease Indications: Matching the Right Targets, Isotopes & Delivery Strategies to Emerging Cancer Opportunities
1:30 pm Beyond Peptides: Advancing Radio-DARPin Therapeutics from Platform Innovation to Clinical Proof-of- Concept
Chief Scientific Officer, Molecular Partners
- Presenting imaging and dosimetry insights from MP0712, a DLL3-targeted Pb-212 Radio-DARPin Therapeutic currently in Phase I development
- Exploring how half-life extended Radio-DARPins are designed to overcome the limitations of conventional peptide-based radiopharmaceutical approaches for challenging targets
- Sharing key learnings from advancing a novel targeted alpha therapy approach across clinical and preclinical development programmes
2:00 pm Expanding Radiopharmaceuticals Beyond Established Indications Through Engineered Scaffold Proteins
Chief Scientific Officer, Affibody AB
Chief Scientific Officer & Vice President - Research, Affibody AB
- Leveraging Affibody molecules to target HER2, HER3, B7-H3 and other emerging oncology targets
- Expanding RLTs into breast, gastric, ovarian, lung and other solid tumours through improved tumour penetration
- Selecting the optimal targeting scaffold for challenging tumour biology
- Translating novel targets into clinically viable radiopharmaceutical programmes
2:30 pm Advancing CAIX-Targeted Radiopharmaceuticals: Developing Next-Generation Precision Diagnostics for Clear Cell Renal Cell Carcinoma
Chief Technology Officer, Norroy North America Inc.
- Evaluating the clinical rationale for targeting CAIX to improve the detection and characterisation of clear cell renal cell carcinoma
- Optimising small molecule radiopharmaceutical design to enable same-day imaging and improved detection of primary and metastatic disease
- Generating early clinical evidence through investigator-initiated studies to validate target engagement, imaging performance and clinical translation
Translational & Clinical Track
Supply Chain & CMC
3:00 pm Afternoon Break & Networking
Translating TRP Innovation into Commercial Reality: Lessons for Scaling Access, Infrastructure & Market Adoption
3:30 pm From Spot Supply to Strategic Control: What Bicycle’s ²¹²Pb Infrastructure Strategy Signals for the Future of TRP Supply Security
- Assessing the therapeutic potential of Lead-212 and the clinical rationale supporting its continued development
- Exploring the logistical and supply challenges associated with short half-life isotopes and how developers can successfully navigate them
- Understanding the balance between operational complexity and potential clinical advantages when selecting radionuclides
4:00 pm From Scientific Promise to Commercial Reality: How Should the Industry Prioritise the Next Generation of Radioligand Therapy Opportunities?
- Evaluating which targets, indications and development strategies are most likely to translate into clinically impactful and commercially successful radioligand therapies
- Understanding how leading organisations assess emerging opportunities and differentiate between promising innovation and crowded market segments
- Exploring how competitive intelligence, early clinical data and evolving market dynamics can be leveraged to inform portfolio and investment decisions
4:30 pm Future Directions Panel Discussion: One Final Question: What Must the TRP Community Solve Before We Meet Again?
- Identifying the single highest-priority challenge that must be solved to accelerate the next generation of radiopharmaceutical development
- Aligning scientific, clinical, regulatory and commercial perspectives to define the industry’s most critical priorities for the year ahead
- Shaping a shared roadmap for the innovations, collaborations and breakthroughs needed before reconvening at the 9th Targeted Radiopharmaceuticals Summit Europe